Genetic diversity and drug resistance mutations of HIV-1 in Leningrad Region

Aleksandr N. Shchemelev1, Aleksandr V. Semenov2, Yulia V. Ostankova1, Elena B. Zueva1, Diana E. Valutite1, Daria A. Semenova1, Vladimir S. Davydenko1, Areg A. Totolian1

1St. Petersburg Pasteur Institute, Saint Petersburg, Russia;
2Ekaterinburg Research Institute of Viral Infections, State Research Center of Virology and Biotechnology “Vector”, Yekaterinburg, Russia

Abstract

Introduction. The spread of the human immunodeficiency virus type 1 (HIV-1) has become a global concern and has approached the pandemic status. St. Petersburg, a major transportation, tourist, cultural, industrial center, and a border city, is characterized by high migration of the population. The growing number of migrants can contribute to importation and spread of new genetic variants of the virus and trigger recombination processes in the virus population in St. Petersburg and the Leningrad Region.

The aim is to characterize the present-day HIV-1 subtype-specific profile and drug-resistance mutations among patients with virological failure on antiretroviral therapy (ART) in the Leningrad Region.

Materials and methods. The study performed in 2016–2018 was based on clinical material from HIV-infected individuals living in the Leningrad Region and having confirmed virological failure on ART. The genetic diversity and distribution of drug-resistance mutations of the HIV-1 isolates were assessed through analysis of nucleotide sequences of the virus pol gene fragment that included regions encoding protease and the reverse transcriptase region.

Results. In the group (n = 138), most of the patients had sub-subtype A6 (97.4%) common in Russia, though a few patients had subtype B and a recombinant containing circulating recombinant form CRF_03AB and sub-subtype A1. The tests showed that 95.79% of patients had at least one significant drug-resistance mutation; in most cases (73%) the virus was resistant to 2 classes of antiretroviral drugs and in some cases (8%) — to 3 classes. A total of 105 different drug-resistance mutations were found at 35 positions of the virus genome.

Conclusions. The high prevalence of HIV-1 drug-resistance mutations among ART patients with virological failure calls attention to surveillance of drug resistance of the virus both among ART-experienced patients and ART-naïve individuals.

Keywords: HIV-1, HIV-1 drug resistance, HIV-1 genotyping, antiretroviral therapy, molecular epidemiology

Ethics approval. The study was conducted with the informed consent of the patients. The research protocol was approved by the Ethics Committee of the St. Petersburg Pasteur Institute (Protocols No. 3, April 7, 2010, and No. 47, December 25, 2018).

Funding source. This study was not supported by any external sources of funding.

Conflict of interest. The authors declare no apparent or potential conflicts of interest related to the publication of this article.

Генетическое разнообразие и мутации лекарственной устойчивости ВИЧ-1 в Ленинградской области

Щемелев А.Н.1, Семенов А.В.2, Останкова Ю.В.1, Зуева Е.Б.1, Валутите Д.Э.1, Семенова Д.А.1, Давыденко В.С.1, Тотолян А.А.1

1Санкт-Петербургский НИИ эпидемиологии и микробиологии имени Пастера, Санкт-Петербург, Россия; 2Екатеринбургский научно-исследовательский институт вирусных инфекций Государственного научного центра вирусологии и биотехнологии «Вектор» Роспотребнадзора, Екатеринбург, Россия

Аннотация

Введение. Проблема распространения вируса иммунодефицита человека первого типа (ВИЧ-1) к настоящему времени обрела общемировое значение и фактический статус пандемии. В Санкт-Петербурге — крупном транспортном, туристическом, культурном, промышленном и приграничном центре — наблюдается высокая миграционная активность населения. Это может способствовать заносу и распространению новых генетических вариантов вируса, а также рекомбинационным процессам в вирусной популяции Санкт-Петербурга и Ленинградской области.

Цель — охарактеризовать современный субтипический профиль и мутации лекарственной устойчивости ВИЧ-1 среди пациентов с вирусологической неэффективностью антиретровирусной терапии (АРТ) в Ленинградской области

Материалы и методы. В ходе работы в 2016–2018 гг. был исследован клинический материал от ВИЧ-инфицированных лиц из Ленинградской области с подтверждённой вирусологической неэффективностью АРТ. Для оценки генетического разнообразия и структуры мутаций лекарственной устойчивости полученных изолятов ВИЧ-1 проводили анализ нуклеотидных последовательностей фрагмента гена pol вируса, включающего области, кодирующие протеазу и участок обратной транскриптазы.

Результаты. В обследованной группе (n = 138) преобладал характерный для России субсубтип A6 (97,4%), однако в единичных случаях были обнаружены субтип B и рекомбинант, образованный циркулирующей рекомбинантной формой CRF_03AB и субсубтипом A1. По результатам анализа у 95,79% пациентов выявлена хотя бы одна значимая мутация лекарственной устойчивости, чаще всего (73% случаев) вирус был устойчив к 2 классам антиретровирусных препаратов, но иногда (8% случаев) — к 3 классам. Всего были определены 105 различных мутаций фармакорезистентности в 35 позициях генома вируса.

Выводы. Учитывая высокую встречаемость мутаций фармакорезистентности ВИЧ-1 у пациентов с вирусологически неэффективной АРТ, представляется необходимым надзор за лекарственной устойчивостью вируса как у получающих АРТ, так и у АРТ-наивных лиц.

Ключевые слова: ВИЧ-1, лекарственная устойчивость ВИЧ-1, генотипирование ВИЧ-1, антиретровирусная терапия, молекулярная эпидемиология


Источник финансирования. Авторы заявляют об отсутствии внешнего финансирования при проведении исследования.

Конфликт интересов. Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.


DOI: https://doi.org/10.36233/0372-9311-216

Introduction

According to UNAIDS1, 31.6-44.5 million people are currently living with human immunodeficiency virus (HIV) worldwide; in 2019, 1.2–2.2 million people became newly infected with HIV [1].

One of the distinctive characteristics of HIV is its high genetic diversity. There are two types of HIV, out of which HIV type 1 (HIV-1) is the most common type. The global distribution of HIV subtypes/sub-subtypes is not homogeneous and varies across geographic regions. Subtype B is the dominant HIV-1 clade in Western and Central Europe; however, in Russia and CIS countries, due to specific features of the epidemic process in the region, subtype B is the second most common HIV variant, while the leading place is taken by special sub-subtype A6 also known as IDU-A (from injecting drug users) or A-FSU (from former Soviet Union countries). This sub-subtype was previously classified as A1, but due to significant differences from

---

other HIV-1 sub-subtype A1 variants in structure and transmission, it was moved into an individual, relatively uniform group [2, 3].

In Russia, there are also HIV-1 recombinant forms combining genome fragments typical of several different subtypes. These virus variants result from the recombination during reverse transcription, when reverse transcriptase (RT) switches the template between two co-packaged genomes, generating a chimeric DNA molecule [1, 3]. If recombinant forms are fully sequenced and detected at least in 3 epidemiologically unrelated patients, they are referred to as circulating recombinant forms (CRF). Complex viruses (cpx) represent recombinants of 4 and more subtypes [1]. With the dynamic nature of the HIV-1 pandemic, the number of identifiable CRF is growing steadily, and currently more than 100 CRF have been identified.

Fast evolution of the virus, its molecular and genetic variability resulting from multiple errors made during replication, high mutation and recombination rates of RT enzyme, and non-uniform fixation rate in nucleotide substitutions during molecular evolution lead not only to generation of a large number of subtypes and recombinant forms, but also to accumulation of mutations, some of which can be clinically significant [4]. Although highly active antiretroviral therapy (ART), the primary goal of which is suppression of viral replication, significantly improves the prognosis for HIV-infected patients, reduces mortality and the number of complications associated with HIV-1, improves the survival rate among patients, drug-resistance (DR) mutations of the virus pose a growing threat to the long-term effect of antiretroviral drugs (ARD) [5]. HIV-1 DR to drugs of several groups is becoming of special concern, significantly limiting the capabilities of therapy [6].

HIV infection belongs to the so-called socially significant diseases that pose a threat to the public; it is also declared a threat to national security. During the first six months in 2020, in Russia, there were 38,126 individuals with detected HIV-1 antibodies; by the end of the first half of 2020, there were 1,094,050 Russians with the laboratory confirmed diagnosis of HIV infection. According to the Federal AIDS Center, 5.5% of ARD-naive patients have drug resistance.

The Leningrad Region, a constituent entity of the Russian Federation, is located in the northwest of European Russia. St. Petersburg is the regional center of federal significance; it has an important influence on the region under study.

In St. Petersburg, the HIV infection epidemic started in the late 1980s and was of a relatively small size, as the infection was spread mostly among high-risk groups through sexual contact; the group of the infected was small and was characterized by the dominance of subtype B. In the later years, the number of people in the high-risk group increased significantly when the virus was transmitted into the cohort of injecting drug users. The mid-1990s marked an avalanche-like epidemic spread of HIV-1 in Russia [7, 8]. In the group of injecting drug users, the highest prevalence rates were recorded for sub-subtype A6, and injections became a major route of HIV-1 transmission [9].

Although during the first six months of 2020, the incidence in St. Petersburg and the Leningrad Region did not exceed the average rates across the country, the above regions fall into the category of most affected by HIV infection. Currently, heterosexual transmission is a dominant route of HIV infection. The literature data demonstrate that HIV-1 sub-subtype A6 prevails in the studied region, though there are other concurrently circulating subtypes [10].

The most recent data on prevalence of HIV drug resistance among ART patients with virological failure in St. Petersburg were obtained in 2012 [9], while the information about the current situation pertaining to secondary DR of the virus is almost non-existent. No DR related data about patients in the Leningrad Region can be found in literature.

St. Petersburg, a major transportation, tourist, cultural, industrial center, and a border city, is characterized by high migration of the population. The growing number of migrants can contribute to importation and spread of new genetic variants of the virus and trigger recombination processes in the virus population of the region.

The aim of the study was to characterize the present-day HIV-1 subtype-specific profile and drug-resistance mutations among ART patients with virological failure in the Leningrad Region.

Materials and methods

The study performed in 2016-2018 was based on the clinical material collected from 138 patients living
in the Leningrad Region and having confirmed virological failure on ART. The material was collected with the voluntary informed consent of the patients. The blood plasma was delivered to the North-West District Center for AIDS Prevention and Control of the St. Petersburg Pasteur Research Institute of Epidemiology and Microbiology to be examined for HIV DR.

The blood plasma was used for viral load tests using the commercial AmpliSens® HIV-Monitor-FRT kit (Central Research Institute of Epidemiology, Russia) with the sensitivity threshold of 500 copies/mL. Samples with detectable viral loads were further tested through RT-PCR and Sanger sequencing. Commercial RT-PCR-kit-Pro/Rev and PCR-kit-Pro/Rev (Central Research Institute of Epidemiology, Russia) were used for HIV reverse transcription and amplification; the sequencing reaction was performed in accordance with the manual of the AmpliSens® HIVResist-Seq kit (Central Research Institute of Epidemiology, Russia). The genotyping of HIV-1 was based on the analysis of nucleotide sequences of the pol gene fragment of 1,302 nt, encoding protease (PR) and part of RT in the 2,253–3,554 nt region; the coordinates are given for HIV HXB2 (GenBank accession number K03455.1) in the international GenBank database. The products of the sequencing reaction were analyzed using the ABI Prism 3500 genetic analyzer (Applied Biosystems).

The primary analysis of nucleotide sequences was performed using the NCBI Blast program to compare with nucleotide sequences available in the international GenBank database. The alignment of nucleotide sequences was performed using the MEGAv.7.0 program and the ClustalW algorithm [11]. For phylogenetic trees and for the subsequent phylogenetic analysis, we used the Neighbor-joining algorithm to optimize trees in accordance with the balanced minimum evolution criterion; to assess the reliability of phylogenetic relationships, we used the bootstrap method to generate multiple samples for 1,000 independent constructions of each phylogenetic tree.

The genotyping of studied isolates was performed both using the REGA HIV-1 Subtyping Tool v.3.0 program and the analysis of their phylogenetic relationships with reference sequences from the international GenBank database. To identify and analyze recombinant forms, we used the REGA HIV-1 Subtyping Tool v.3.0 program and the parameters preset in the program (window size — 400 bp; step size — 20). The HIV-1 genetic sequences were assessed for DR mutations using the Stanford database.

Results

Out of 138 patients, more than a half (59%) were men. In the study group, most of the patients were of 35-44 years old (60%); the median age was 36 years (Fig. 1). All the patients had a HIV-1 viral load exceeding 1,000 copies/mL, thus making it possible to obtain virus genome sequences encoding protease and RT region.

Two methods of typing, the phylogenetic analysis and the analysis of sequences using the REGA HIV-1 Subtyping Tool v.3.0 program to improve the accuracy of distribution of HIV-1 subtypes, demonstrated the following distribution of HIV-1 subtypes: sub-subtype A6 common for Russia prevailed (98%); few cases had subtype B (1%) and a recombinant of the circulating recombinant form CRF_03AB and sub-subtype A1 (1%) (Fig. 2, Table 1).

The analysis showed that 96% of patients had at least one significant mutation associated with DR for the respective sub-subtype of the virus. We found a total of 105 different DR mutations at 35 positions of the pol gene of the HIV-1 virus (Fig. 3). Most of the detected mutations (89%) cause DR to nucleoside reverse transcriptase inhibitors (NRTIs) (43%) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (47%). Among the detected mutations, the smallest proportion (11%) is represented by mutations associated with resistance to protease inhibitors (PIs). The mutations that are most frequently detected in patients are presented in Tables 2 and 3.

In most of the detected DR cases (n = 130; 94%) in the analyzed isolates, there were 2 and more mutations. In such patients, the virus is generally resistant to 2 classes of ARDs (n = 101; 73%) and sometimes to 3 classes of ARDs (n = 11; 8%).

Some of the obtained and analyzed nucleotide sequences of the pol gene region in the HIV-1 isolates were deposited to the international GeneBank database under numbers OL505461-OL505538.
Discussion

The genetic diversity of HIV-1 in the study group correlates with the diversity typical of Russia, demonstrating the absolute dominance of sub-subtype A6. Note that all the isolates were classified as sub-subtype A1 by genotyping with REGA HIV-1 Subtyping Tool v.3.0; however, our own phylogenetic analysis lets us state with confidence that they belong to sub-subtype A6. This discrepancy can be explained by the fact that the latest versions of the software do not include the data confirming that sub-subtype A6 should be separated from sub-subtype A1. In addition, the only case had a complex recombinant of CRF_03AB and subtype A1, the recombination analysis of which we performed within the pol gene.

Genotyping is critically important for the further testing of the sample for presence of ARD resistant HIV variants, as genetic variants of the virus can differ in their biological properties, virus evolution rate and disease progression as well as by the contribution of different mutations to development of DR to ART. Therefore, additional studies must be conducted to assess the participation of recombinant forms in the genetic diversity of the virus in the region. The lack of attention to the high diversity of HIV recombinants and unavailability of comprehensive data on most common recombination points can result in misidentification of DR in the virus [21].

Particular attention should be given to the difference in the genetic diversity of subtype-specific pro-
files obtained in this study and in the study performed in 2012 [9]. The Leningrad Region is characterized by smaller numbers of detected subtypes as compared to St. Petersburg, thus implying significant disconnectedness between the HIV-infected groups of the region and the city despite their geographic proximity.

The frequency of DR mutations was extremely high among ART patients with virological failure. Mutations to RT inhibitors were most frequently detected, while mutations associated with resistance to PIs were detected only in 8 (6%) cases, thus leading to assumption that it can be explained by a higher genetic barrier to DR in PIs and by their less frequent use in treatment regimens administered to the examined patients [22, 23]. Compared with the 2012 data on St. Petersburg, the frequency of detection of HIV-1 DR mutations increased more than 3-fold: from 30% to 95% [9]. The increased number of resistant virus variants can be explained by changes in the HIV-infected population in Russia: during this period, the epidemic went beyond the vulnerable groups of the population, affecting a larger number of HIV-infected people of higher social status. The ARD patients demonstrated increased adherence. There was an increased number of patients with suboptimal treatment adherence, which is a significant contributor to the risk of DR development [24]. At the same time, the region demonstrates an increasing frequency of transmitted primary resistance, which, undoubtedly, contributes to DR prevalence among ARD people, as currently there is no patients’ screening for RD mutations prior to their treatment [10].

In addition to the frequency of mutations, there were changes in their distribution (Fig. 3). The most frequently detected mutation is \textit{M184V} (n = 106; 77%). The second most frequent mutation is \textit{Q151M} (n = 70; 51%), which is associated with DR to several NRTIs; note that it was not reported in 2012 [9]. In 2012, the third most frequent mutations were \textit{G190S} (47%) and \textit{K103N} (13%) associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%), and they are also associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%), and they are also associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%), and they are also associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%), and they are also associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%), and they are also associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%), and they are also associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%), and they are also associated with virus DR to NNRTIs; in this study, the 3rd place is occupied by mutations at the 101st position (n = 65; 47%).

\textbf{Table 1. GenBank reference sequences used in the phylogenetic analysis}

<table>
<thead>
<tr>
<th>Sub-subtype</th>
<th>GenBank sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>AF069670_A1_Somalia</td>
</tr>
<tr>
<td>A1</td>
<td>AB287376_A1_Ruanda</td>
</tr>
<tr>
<td>A1</td>
<td>U51190_A1_Uganda</td>
</tr>
<tr>
<td>A1</td>
<td>EU110087_A1_Kenya</td>
</tr>
<tr>
<td>A1</td>
<td>AF484509_A1_Uganda</td>
</tr>
<tr>
<td>A1</td>
<td>AF107771_A_Sweden</td>
</tr>
<tr>
<td>A2</td>
<td>AF286237_A2_Cyprus</td>
</tr>
<tr>
<td>A3</td>
<td>AYS21631_A3_Senegal</td>
</tr>
<tr>
<td>A3</td>
<td>AYS21629_A3_Sweden</td>
</tr>
<tr>
<td>A6</td>
<td>HQ449397_A6_Krasnodar</td>
</tr>
<tr>
<td>A6</td>
<td>HQ161930_A6_Smolensk</td>
</tr>
<tr>
<td>A6</td>
<td>EFS89043_A6_Kazakhstan</td>
</tr>
<tr>
<td>A6</td>
<td>AY500393_A6_Moscow</td>
</tr>
<tr>
<td>A6</td>
<td>AF413987_A6_Kiev</td>
</tr>
<tr>
<td>B</td>
<td>M17449_B_USA</td>
</tr>
<tr>
<td>B</td>
<td>KJ771697_B_Germany</td>
</tr>
<tr>
<td>B</td>
<td>HM586190_B_UK</td>
</tr>
<tr>
<td>B</td>
<td>AY713409_B_USA</td>
</tr>
<tr>
<td>B</td>
<td>AY173951_B_Thailand</td>
</tr>
<tr>
<td>C</td>
<td>AF067155_C_India</td>
</tr>
<tr>
<td>C</td>
<td>U52953_C_Brazil</td>
</tr>
<tr>
<td>C</td>
<td>U46016_C_Ethiopia</td>
</tr>
<tr>
<td>C</td>
<td>AY772699_C_Africa</td>
</tr>
<tr>
<td>F1</td>
<td>AF075703_F1_Finland</td>
</tr>
<tr>
<td>G</td>
<td>AF061641_G_Finland</td>
</tr>
<tr>
<td>G</td>
<td>U88826_G_Nigeria</td>
</tr>
<tr>
<td>G</td>
<td>AF084936_G_Gongo</td>
</tr>
<tr>
<td>CRF 02AG</td>
<td>AF063224_CRF02_AG_Djibouti</td>
</tr>
<tr>
<td>CRF 02AG</td>
<td>GU201514_CRF02_AG_Cameroon</td>
</tr>
<tr>
<td>CRF 06cpx</td>
<td>HQ529257_1_Ghana_crf_06cpx</td>
</tr>
<tr>
<td>CRF02_AG</td>
<td>KT124792_CRF02_AG_Germany</td>
</tr>
<tr>
<td>CRF02_AG</td>
<td>AB231898_CRF02_AG_Ghana</td>
</tr>
<tr>
<td>CRF02_AG</td>
<td>EU786671_CRF02_AG_Spain</td>
</tr>
<tr>
<td>CRF02_AG</td>
<td>AB231896_CRF02_AG_Ghana</td>
</tr>
<tr>
<td>CRF02_AG</td>
<td>AY151001_CRF02_AG_Ecuador</td>
</tr>
<tr>
<td>CRF02_AG</td>
<td>AF377954_CRF02_AG_Cameroon</td>
</tr>
<tr>
<td>CRF03_AB</td>
<td>AF193276_CRF03_AB_Kaliningrad</td>
</tr>
<tr>
<td>CRF06_cpx</td>
<td>MH605500.1_Guinea-Bissau_crf_06cpx</td>
</tr>
</tbody>
</table>
patients with virological failure from other regions of the North-West Federal District of the Russian Federation. For example, in Arkhangelsk sub-subtype A6 (90%) prevailed as compared to subtype B (9%); the CRF03_AB variant was detected in 1 (1%) case. In the group from Arkhangelsk, DR mutations were detected in a smaller number of patients (86.7%) as well as multiple (2 and more) mutations were detected in a smaller number of patients (81.9%), though there were no significant differences. Mutations to RT inhibitors were detected more frequently (84%) than mutations to PIs (16%); isolates with DR only to NRTIs accounted for 17%, isolates with DR only to NNRTIs — 2%, with DR only to PIs — 11%, with DR both to PIs and NRTIs — 12%, with DR to NRTIs and NNRTIs — 47%, with DR to all 3 groups of inhibitors — 12% [26]. Although mutations demonstrate quite similar prevalence rates, their distribution is different. Among patients from Arkhangelsk, mutation M184V had the highest prevalence of 72% (67% of all the mutations), similar to the results obtained during this study. At the same time, the prevalence of mutations K103N (33%) and G190S (a little less than 25%) is more similar to the prevalence reported in the study performed in St. Petersburg in 2012. The similar prevalence of the above mutations was recorded among HIV-infected ART patients with virological failure in Novgorod [27].

Conclusions

HIV-1 A6 (IDUA) remains the dominant genetic HIV-1 variant in the Leningrad Region among patients with virological failure on ART. It has been found that the frequency of HIV-1 DR mutations increased significantly compared to 2012. In all cases, among samples with DR mutations, there were mutations to 2 or 3 groups of drugs. The high prevalence of HIV-1 DR mutations among ART patients with virological failure calls attention to surveillance of HIV-1 DR both among ART-experienced patients and ART-naïve individuals. Lack of surveillance can result in increasing numbers of HIV patients with primary resistance to ART.

Further studies of HIV-1 molecular and epidemic diversity will be essential for monitoring the spread and escalation of the HIV epidemic.

Table 2. Most frequent HIV DR mutations in the examined patients

<table>
<thead>
<tr>
<th>Mutation</th>
<th>Frequency</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>M184V</td>
<td>106 (77%)</td>
<td>Causes high-level resistance in vitro to 3TC and FTC and low-level resistance to ddl and ABC [12]</td>
</tr>
<tr>
<td>Q151M</td>
<td>70 (51%)</td>
<td>Causes intermediate/high-level resistance to AZT, ddI, d4T, and ABC and low-level resistance to TDF, 3TC, and FTC [13]</td>
</tr>
<tr>
<td>K101E</td>
<td>65 (47%)</td>
<td>Causes intermediate-level resistance to NVP and RPV, low-level resistance to EFV and potentially low-level resistance to ETR [14]</td>
</tr>
<tr>
<td>Y181C</td>
<td>37 (27%)</td>
<td>Reduces susceptibility to NVP, ETR, RPV, and EFV more than by 50-fold, 5-fold, 3-fold, and 2-fold, respectively [15]</td>
</tr>
<tr>
<td>K65R</td>
<td>37 (27%)</td>
<td>Causes intermediate/high-level resistance to TDF, ddI, ABC, and d4T, and low/intermediate-level resistance to 3TC and FTC. Increases susceptibility to AZT [16]</td>
</tr>
<tr>
<td>D67N</td>
<td>28 (20%)</td>
<td>Associated with low-level resistance to AZT and d4T, and contributes to reduced susceptibility to ABC, ddI, and TDF [17]</td>
</tr>
<tr>
<td>K103N</td>
<td>26 (19%)</td>
<td>Causes a significant decrease in susceptibility to NVP and EFV [17]</td>
</tr>
<tr>
<td>E138A</td>
<td>22 (16%)</td>
<td>Reduces susceptibility to ETR and RPV approximately by 2-fold [18]</td>
</tr>
<tr>
<td>G190S</td>
<td>19 (14%)</td>
<td>Causes high-level resistance to NVP and EFV [19]</td>
</tr>
<tr>
<td>V90I</td>
<td>18 (13%)</td>
<td>Associated with a minimum decrease in susceptibility to NNRTIs [20]</td>
</tr>
</tbody>
</table>

Table 3. Frequency of the most common combinations of HIV DR mutations in the examined patients

<table>
<thead>
<tr>
<th>Mutations</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>M184V + K101E</td>
<td>29 (21%)</td>
</tr>
<tr>
<td>M184V + K103N</td>
<td>19 (14%)</td>
</tr>
<tr>
<td>M184V + K101E + G190S</td>
<td>17 (12%)</td>
</tr>
<tr>
<td>M184V + Q151M + K103N</td>
<td>16 (11%)</td>
</tr>
<tr>
<td>M184V + G190S</td>
<td>7 (5%)</td>
</tr>
</tbody>
</table>

References


27. Shafer R.W., Rhee S.Y., Bennett D.E. Consensus resistance mutations for epidemiological surveillance: basic principles and
https://doi.org/10.22328/2077-9828-2021-13-1-70-79
https://doi.org/10.1093/molbev/msw054
https://doi.org/10.1097/QAD.0000000000000404
23. Котова В.О., Троцюк Е.О., Балахонцева Л.А., Балыкина Е.А. Молекулярно-генетическая характеристика вариантов ВИЧ-1, выделенных в субъектах Дальневосточного федерального округа. ВИЧ-инфекция и иммуносупрессия. 2019; 64(2): 79–89.
Информация об авторах
Щемелев Александр Николаевич — м.н.с. лаб. вирусологии и иммунологии ВИЧ-инфекции, аспирант НИИЭМ им. Пастера, Санкт-Петербург, Россия, tvildorm@gmail.com, https://orcid.org/0000-0002-3139-3674
Семенов Александр Владимирович — д.б.н., руководитель ЕНИИВИ ГНЦ ВБ «Вектор», Екатеринбург, Россия, https://orcid.org/0000-0003-3223-8219
Останкова Юлия Владимировна — к.б.н., зав. лаб. вирусологии и иммунологии ВИЧ-инфекции НИИЭМ им. Пастера, Санкт-Петербург, Россия, https://orcid.org/0000-0004-2270-8897
Зуева Елена Борисовна — к.б.н., с.н.с. лаб. экспериментальной вирусологии НИИЭМ им. Пастера, Санкт-Петербург, Россия, https://orcid.org/0000-0002-0579-110X
Валутите Диана Эдуардовна — врач клинической лабораторной диагностики отделения ВИЧ-инфекции и СПИД-ассоциированных заболеваний НИИЭМ им. Пастера, Санкт-Петербург, Россия, https://orcid.org/0000-0002-0931-102X
Семенова Дарья Андреевна — сотрудник лаб. вирусологии и иммунологии ВИЧ-инфекции НИИЭМ им. Пастера, Санкт-Петербург, Россия, https://orcid.org/0000-0002-0931-102X
Дацыненко Владимир Сергеевич — лаборант-исследователь лаб. вирусологии и иммунологии ВИЧ-инфекции, аспирант НИИЭМ им. Пастера, Санкт-Петербург, Россия, https://orcid.org/0000-0002-0579-110X
Тотолян Арег Артемович — д.м.н., профессор, академик РАН, зав. лаб. молекулярной иммунологии, директор НИИЭМ им. Пастера, Санкт-Петербург, Россия, https://orcid.org/0000-0003-4571-8799
Участие авторов. Все авторы внесли существенный вклад в проведение поисково-аналитической работы и подготовку статьи, прочли и одобрили финальную версию до публикации.

Статья поступила в редакцию 13.12.2021; принята к публикации 12.02.2022; опубликована 28.02.2022

Information about the authors
Aleksandr N. Shchemelev — junior researcher, Laboratory of virology and immunology of HIV infection, postgraduate student, St. Petersburg Pasteur Institute, St. Petersburg, Russia, tvildorm@gmail.com, https://orcid.org/0000-0002-3139-3674
Aleksandr V. Semenov — D. Sci. (Biol.), Head, Ekaterinburg Research Institute of Viral Infections, State Research Center of Virology and Biotechnology “Vector”, Yekaterinburg, Russia, https://orcid.org/0000-0003-3223-8219
Yulia V. Ostankova — Cand. Sci. (Biol.), Head, Laboratory of virology and immunology of HIV infection, St. Petersburg Pasteur Institute, St. Petersburg, Russia, https://orcid.org/0000-0003-2270-8897
Elena B. Zueva — Cand. Sci. (Biol.), senior researcher, Laboratory of experimental virology, St. Petersburg Pasteur Institute, St. Petersburg, Russia, https://orcid.org/0000-0002-0579-110X
Diana E. Valutite — doctor of clinical laboratory diagnostics, Department for diagnosing HIV infection and AIDS-related diseases, St. Petersburg Pasteur Institute, St. Petersburg, Russia, https://orcid.org/0000-0002-0931-102X
Daria A. Semenova — employee, Laboratory of virology and immunology of HIV infection, St. Petersburg Pasteur Institute, St. Petersburg, Russia, https://orcid.org/0000-0002-2599-5142
Vladimir S. Davydenko — research laboratory assistant, Laboratory of virology and immunology of HIV infection, St. Petersburg Pasteur Institute, St. Petersburg, Russia, https://orcid.org/0000-0002-0787-9681
Areg A. Totolian — D. Sci. (Med.), Professor, Full Member of RAS, Head, Laboratory of molecular immunology, Director, St. Petersburg Pasteur Institute, St. Petersburg, Russia, https://orcid.org/0000-0003-4571-8799

Author contribution. All authors made a substantial contribution to the conception of the work, acquisition, analysis, interpretation of data for the work, drafting and revising the work, final approval of the version to be published.

The article was submitted 13.12.2021; accepted for publication 12.02.2022; published 28.02.2022